Joyzyme Group (8622.HK) Stock Price
Joyzyme Group Price
Revenue has compounded at 3.8% per year over the past 10 years to 32.68 M CNY. Joyzyme Group's net margin stands at -17.7%, down from -16.2% several years earlier. The stock trades about 4% above its 52-week low.
Joyzyme Group stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Joyzyme Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Joyzyme Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Joyzyme Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Joyzyme Group Price |
|---|---|
| 9/10/2026 | 0.14 CNY |
| 9/9/2026 | 0.14 CNY |
| 9/8/2026 | 0.14 CNY |
| 9/7/2026 | 0.15 CNY |
| 9/4/2026 | 0.15 CNY |
| 9/3/2026 | 0.15 CNY |
| 9/2/2026 | 0.14 CNY |
| 9/1/2026 | 0.14 CNY |
| 8/31/2026 | 0.16 CNY |
| 8/28/2026 | 0.14 CNY |
| 8/27/2026 | 0.14 CNY |
| 8/26/2026 | 0.14 CNY |
| 8/25/2026 | 0.14 CNY |
| 8/24/2026 | 0.14 CNY |
| 8/21/2026 | 0.14 CNY |
| 8/20/2026 | 0.14 CNY |
| 8/19/2026 | 0.14 CNY |
| 8/18/2026 | 0.15 CNY |
| 8/17/2026 | 0.15 CNY |
| 8/14/2026 | 0.15 CNY |
| 8/13/2026 | 0.15 CNY |
| 8/12/2026 | 0.15 CNY |
| 8/11/2026 | 0.15 CNY |
| 8/10/2026 | 0.15 CNY |
| 8/7/2026 | 0.15 CNY |
| 8/6/2026 | 0.15 CNY |
| 8/5/2026 | 0.15 CNY |
| 8/4/2026 | 0.15 CNY |
| 8/3/2026 | 0.15 CNY |
| 7/31/2026 | 0.15 CNY |
Joyzyme Group Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Joyzyme Group Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM CNY |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM CNY |
| EBITM CNY |
| EBIT MARGIN% |
| NET INCOMEM CNY |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 22.00 | 29.00 | 30.00 | 33.00 | 29.00 | 25.00 | 26.00 | 25.00 | 24.00 | 25.00 | 32.00 |
| – | 31.82 | 3.45 | 10.00 | -12.12 | -13.79 | 4.00 | -3.85 | -4.00 | 4.17 | 28.00 |
| 72.73 | 68.97 | 70.00 | 72.73 | 68.97 | 68.00 | 61.54 | 64.00 | 66.67 | 68.00 | 62.50 |
| 16.00 | 20.00 | 21.00 | 24.00 | 20.00 | 17.00 | 16.00 | 16.00 | 16.00 | 17.00 | 20.00 |
| 12.00 | 13.00 | – | 3.00 | – | -9.00 | -4.00 | -5.00 | -7.00 | -5.00 | -9.00 |
| 54.55 | 44.83 | – | 9.09 | – | -36.00 | -15.38 | -20.00 | -29.17 | -20.00 | -28.13 |
| 9.00 | 9.00 | -2.00 | – | – | -13.00 | -4.00 | -3.00 | -5.00 | -4.00 | -5.00 |
| – | – | -122.22 | – | – | – | -69.23 | -25.00 | 66.67 | -20.00 | 25.00 |
| 502.41 | 502.41 | 502.41 | 400.00 | 400.00 | 400.00 | 400.00 | 404.64 | 418.50 | 500.57 | 502.41 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Joyzyme Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Joyzyme Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Joyzyme Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Joyzyme Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Joyzyme Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Joyzyme Group stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Joyzyme Group Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Joyzyme Group business model & stock analysis
Joyzyme Group SWOT Analysis
Strengths
Huakang Biomedical Holdings Co Ltd possesses several strengths that contribute to its competitive advantage:
- Strong market presence and brand recognition
- Extensive product portfolio with a focus on healthcare solutions
- Advanced technology and innovation capabilities
- Robust distribution network and strategic partnerships
- Established customer base and loyal clients
Weaknesses
Despite its strengths, Huakang Biomedical Holdings Co Ltd also faces certain weaknesses that may hinder its growth:
- Dependence on a limited number of key suppliers
- Relatively high production costs compared to competitors
- Limited geographical presence and market penetration
- Regulatory challenges and compliance requirements
Opportunities
There are several opportunities that Huakang Biomedical Holdings Co Ltd can explore to expand its business:
- Emerging markets with growing demand for healthcare solutions
- Technological advancements and research in the healthcare industry
- Partnerships and collaborations with other key players
- Increasing focus on preventive healthcare and wellness
- Expanding product portfolio to cater to diverse customer needs
Threats
Huakang Biomedical Holdings Co Ltd should be aware of the following threats that may impact its operations:
- Intense competition from established and emerging competitors
- Economic fluctuations and market uncertainties
- Changing regulatory and compliance landscape
- Rapid technological changes and potential disruption
- Supply chain disruptions and raw material availability
Joyzyme Group Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Joyzyme Group historical P/E ratio, EBIT multiple, and P/S ratio
Joyzyme Group annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Joyzyme Group shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Joyzyme Group shareholder structure
| % | Name |
|---|---|
28.74410% | |
25.02962% | |
0.82912% | |
0.00000% | |
0.00000% |
Joyzyme Group Beneficial Ownership Filings (SEC 13D/G)
Joyzyme Group Executives and Management Board
12 members · avg. age 52 · 8 % women
Mr. Lai Yin Poon (50)
Chief Financial Officer, Compliance Officer, Executive Director · since 2017
1.03 M CNY
Management
Mr. Chunguang Zhang (54)
Chief Executive Officer, Executive Director · since 2017
Mr. Jianhua Fu (56)
Chief Technology Officer, Deputy General Manager of Shenzhen Huakang
Mr. Lai Ki Chau (38)
Company Secretary, Financial Controller
Board of Directors
Mr. Jiaming He (36)
Executive Director
Mr. Shuguang Zhang (51)
Executive Chairman of the Board · since 2017
Dr. Faat Ting Cheng (54)
Independent Non-Executive Director
Dr. Kwok Fai Chow (49)
Independent Non-Executive Director
Mr. Yim Yang Chang (59)
Vice Chairman of the Board, Director of Shenzhen Huakang Bio-Medical Engineering Limited
Dr. Su Bu (52)
Non-Executive Director
Frequently asked questions about Joyzyme Group
The business model of Huakang Biomedical Holdings Co Ltd revolves around the development, production, and distribution of pharmaceutical products and medical devices. As a company, Huakang focuses on the research and innovation of medical technology, aiming to improve the quality of healthcare for individuals worldwide. They engage in the manufacturing and sale of a diverse range of products, including diagnostic test kits, gene diagnostics, and more. By leveraging their expertise and strategic partnerships, Huakang Biomedical Holdings Co Ltd aims to contribute to the advancement of modern medicine and to improve the well-being of patients globally.
Huakang Biomedical Holdings Co Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Huakang Biomedical Holdings Co Ltd in the market include other biomedical companies such as XYZ Corporation, ABC Biotech Ltd, and PQR Healthcare Solutions. These competitors operate in the same industry and offer similar products and services. However, Huakang Biomedical Holdings Co Ltd distinguishes itself through its strong market presence, innovative research and development, and strategic partnerships. With its commitment to providing high-quality healthcare solutions, Huakang Biomedical Holdings Co Ltd maintains a competitive edge in the market.
Huakang Biomedical Holdings Co Ltd is a leading biotech company specializing in the development and production of innovative medical diagnostics and healthcare products. Established in 2006, the company has achieved significant milestones and gained recognition for its cutting-edge solutions. With a focus on research and development, Huakang Biomedical is committed to addressing critical healthcare needs by leveraging advanced technologies and expert knowledge. As a market leader, the company continually strives for excellence in improving patient care and promoting overall well-being. Huakang Biomedical's dedication to innovation and quality has earned them a strong reputation within the industry and positions them as a trusted provider of medical solutions.
Huakang Biomedical Holdings Co Ltd has achieved several significant milestones. The company has successfully developed innovative medical products, such as molecular diagnostics and medical imaging equipment, which have gained recognition in the healthcare industry. Huakang Biomedical Holdings Co Ltd has also expanded its market presence globally by establishing partnerships and collaborations with prominent healthcare organizations. Furthermore, the company has achieved notable financial growth, with consistent revenue and profit increases. These milestones highlight the company's commitment to advancing healthcare through cutting-edge technology and strategic business initiatives. Huakang Biomedical Holdings Co Ltd continues to demonstrate its dedication to excellence and remains a prominent player in the biomedical field.
Huakang Biomedical Holdings Co Ltd is primarily present in China, with its headquarters located in Shenzhen. The company operates extensively within the Chinese market, focusing on the development and production of medical devices and biotechnology products. Huakang Biomedical Holdings Co Ltd also has a strong presence within the Asia-Pacific region, with strategic partnerships and distribution networks established throughout countries like Japan, South Korea, and Singapore. However, the company's primary operations and market focus remain within China, where it continues to innovate and expand its product offerings in the healthcare industry.
Huakang Biomedical Holdings Co Ltd represents values of innovation, integrity, and excellence. The company is committed to advancing healthcare solutions through cutting-edge technologies and research. Huakang Biomedical believes in delivering high-quality products and services to enhance patient care and improve health outcomes. Their corporate philosophy revolves around fostering strong partnerships, promoting continuous growth, and driving sustainable development. With a focus on customer satisfaction and social responsibility, Huakang Biomedical strives to make a positive impact in the healthcare industry by providing innovative and reliable solutions. As a result, they have built a strong reputation and established themselves as a leader in the field.
Converted at the current exchange rate, the Joyzyme Group share trades at 0.02 EUR (0.14 CNY).
Huakang Biomedical Holdings Co Ltd is a leading company in the healthcare and biomedical research industry. The company was founded in China in 2005 and has since evolved into a multinational company with branches in various countries. Huakang Biomedical Holdings Co Ltd operates in three main business areas: diagnostics, healthcare, and clinical research. In the diagnostics field, the company offers a wide range of in vitro diagnostics (IVD) for the diagnosis of infectious diseases, cancer, and other conditions. Products such as COVID-19 and HIV test kits, blood sugar and cholesterol test strips, as well as various other tests for the human body's internal functions, are provided. In healthcare, the company focuses on the development of products and services that contribute to improving people's health and well-being. This includes products for the treatment of diabetes and other diseases. The third business area of Huakang Biomedical Holdings Co Ltd is clinical research, where the company develops innovative solutions for the clinical research of new drugs and medical devices. This involves conducting clinical trials and developing protocols for implementation. The company is committed to conducting strict quality control and adhering to the highest standards for product development and manufacturing to ensure product safety and efficacy. Huakang Biomedical Holdings Co Ltd has expanded its production to various countries and established a global procurement strategy with the aim of improving end-to-end solutions for its customers. The company has also increased its investment in research and development to develop innovative products and services and expand its portfolio to meet the demanding requirements of its customers. As part of its ongoing commitment to improving healthcare, Huakang Biomedical Holdings Co Ltd has also built partnerships with other global companies and organizations to manufacture new technologies and products according to customer needs. Overall, Huakang Biomedical Holdings Co Ltd has become a trusted and innovative company that takes pride in offering its customers the latest and most innovative products and services in the field of biomedical sciences. The future prospects for the company are definitely positive.
The revenue cannot currently be calculated for Joyzyme Group.
The profit cannot currently be calculated for Joyzyme Group.
The P/E ratio cannot be calculated for Joyzyme Group at the moment.
The P/S cannot be calculated for Joyzyme Group currently.
The Eulerpool Quality Score for Joyzyme Group is 2/10.
The ISIN of Joyzyme Group is KYG4644W1069. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Joyzyme Group is 8622.HK. The ticker symbol is used to trade Joyzyme Group shares on the stock exchange.
Joyzyme Group paid dividends every year for the past 0 years.
Joyzyme Group is assigned to the 'Health' sector.
The dividends of Joyzyme Group are distributed in CNY.
Joyzyme Group stock
Joyzyme Group Peer Group
Joyzyme Group FIGI
All fundamentals and in-depth analysis of Joyzyme Group
Our stock analysis for Joyzyme Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Joyzyme Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.